Neurocrine Biosciences (NBIX) Submitted The Valbenazine NDA Earlier Than Expected - Baird

August 30, 2016 6:35 AM EDT
Get Alerts NBIX Hot Sheet
Price: $41.66 -0.12%

Rating Summary:
    15 Buy, 2 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade NBIX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Neurocrine Bio. (NASDAQ: NBIX) after the submission for the valbenazine NDA in tardive dyskinesia came a little earlier than expected. The "Breakthrough Therapy" designation could make an approval come as early as April 2017. AbbVie is on track to file elagolix next year, and with upcoming data in Tourette, NBIX is set for some strong catalysts over the next 12-18 months.

The timing of the NDA filing indicates that a decision on the review will be in by October, with a PDUFA expected around April, assuming an accelerated review. At that rate, the drug could be on the market in the U.S. mid next year.

No change tot the price target of $66.

For an analyst ratings suNeurocrine Biosciences (NASDAQ: NBIX)
of Neurocrine Bio. closed at $49.31 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, FDA

Related Entities

Robert W Baird, PDUFA

Add Your Comment